Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Celso Dias

Vascular Surgery Rochester, NY Medical Doctor

NPI 1396994109 CMS profile 153967

30 Hagen Dr Suite 120, Ste 120, Rochester, NY 14625

Open in the dashboard

General payments

$22,845

219 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Celso Dias of Rochester, NY is reported in the CMS Open Payments database as having received $22,845 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,463 55
2024 General $6,465 32
2023 General $4,852 21
2022 General $967 27
2021 General $1,074 34
2020 General $1,373 21
2019 General $652 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Celso Dias
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Celso Dias were reported at $7,463. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Celso Dias Vascular Surgery median Middle half National median
2019 $652 $796 $226–$2,363 $163
2020 $1,373 $348 $118–$1,110 $114
2021 $1,074 $471 $158–$1,421 $132
2022 $967 $725 $222–$2,183 $149
2023 $4,852 $836 $257–$2,440 $160
2024 $6,465 $909 $252–$2,619 $164
2025 $7,463 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $14,254 6 payments
  2. Medtronic, Inc. $3,305 78 payments
  3. Cardiovascular Systems Inc. $1,020 42 payments
  4. W. L. Gore & Associates, Inc. $895 13 payments
  5. Boston Scientific Corporation $793 31 payments
  6. Terumo Medical Corporation $733 11 payments
  7. Abbott Laboratories $725 19 payments
  8. Philips Electronics North America Corporation $460 9 payments
  9. Cook Medical LLC $323 3 payments
  10. Medtronic Vascular, Inc. $269 6 payments
  11. Other $70 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $13,893 3 payments
  2. Food and Beverage $8,502 215 payments
  3. Consulting Fee $450 1 payment
Products named General payments · program years 2019–2025
  1. VenaCure 1470 Pro Et $9,093 2 payments
  2. VenaCure 1470 Pro Id $4,800 1 payment
  3. Abre $2,208 43 payments
  4. Peripheral Orbital Atherectomy System $534 28 payments
  5. R2P MISAGO $450 1 payment
  6. HawkOne $361 15 payments
  7. Diamondback Peripheral $347 13 payments
  8. (4067) Tack Endo Sys BTK $311 5 payments
  9. ENDURANT IIS $266 1 payment
  10. GORE VIABAHN Endoprosthesis with Heparin $265 4 payments
  11. Other $4,293 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

20

Median for Vascular Surgery: 122

Drug cost

$92

Median for Vascular Surgery: $14,135

Branded share of claims

0%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 20 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$73,029

Medicare's payments for the services billed

Medicare patients

140

Average age 73

Services billed

420

63 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Chronic kidney disease 45%
Arthritis 45%
Ischemic heart disease 40%
Heart failure 39%
Atrial fibrillation 36%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record